| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | Lacidipine 13C8 Basic information |
| Product Name: | Lacidipine 13C8 | | Synonyms: | Lacidipine 13C8;Lacidipine 13C8Q: What is
Lacidipine 13C8 Q: What is the CAS Number of
Lacidipine 13C8 Q: What is the storage condition of
Lacidipine 13C8 Q: What are the applications of
Lacidipine 13C8;13C8]-Lacidipine;Lacidipine-[13C8] (Standard) | | CAS: | 1261432-01-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lacidipine 13C8 Structure]() |
| | Lacidipine 13C8 Chemical Properties |
| | Lacidipine 13C8 Usage And Synthesis |
| Uses | Lacidipine-13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Zhang A, et al. Lacidipine attenuates apoptosis via a caspase-3 dependent pathway in human kidney cells. Cell Physiol Biochem. 2013;32(4):1040-9.
[3] Cristofori P, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000 Oct;18(10):1429-36. DOI:10.1097/00004872-200018100-00010 |
| | Lacidipine 13C8 Preparation Products And Raw materials |
|